Meet top R&D leaders and investors in ShanghaiAdvanced rates end Sept. 19
JOIN THE CONVERSATION

China's Innovation Moment

From cross-border deals to newcos, faster clinical data is fueling the China innovation story, turning biopharmas from Shanghai to Beijing into global players. Multinational pharma and Western VCs have been the first to capitalize, sourcing innovation from China at record levels.

But testing faster in humans is also a recipe for Western and Asia biotechs to de-risk their own compounds, working with China partners.

This October, BioCentury, BayHelix and Insights Partner McKinsey & Company invite you to visit Shanghai for the 12th China Healthcare Summit. Get a firsthand look at China's biotech ecosystem and build your network with the right biopharmas, investors and CDMOs.

Build your network with the right biopharmas, investors & CDMOsThe time to meet in China is now - Join us in Shanghai
REGISTER NOW

MEET THE SPEAKERS

LinkedIn
Amit Kakar
Managing Partner & Head of Asia
Novo Holdings
Jing Lou, Ph.D.
Chairman & CEO
3SBio Inc.
LinkedIn
Deepa Talpade, Ph.D.
VP, Head BD&L and Alliance Management, Oncology and Radiology
Bayer
LinkedIn
Michelle Xia, Ph.D.
Co-Founder, Chairman & CEO
Akeso Inc.
LinkedIn
Michael Yu, Ph.D.
Chairman & CEO
Innovent Biologics
LinkedIn
John Zhu, Ph.D.
Founder & CEO
Duality Biologics
Moreright-arrow

What Will I Learn? 

  • How are China biotechs generating faster clinical data for their assets?

  • What policies have China regulators adopted to help accelerate R&D?

  • How can I source innovation from China?

  • How can China de-risk Western and Asia assets via faster clinical data?

  • What are the top China assets available for licensing or NewCos?

  • Where is China innovation heading next on targets, modalities and indications?

  • Which CDMOs and service providers can help accelerate my pipeline?

  • What licensing and NewCo opportunities are available in Korea, Singapore and other emerging Asia markets?

Organizing Committee

LinkedIn
Guo-Liang Yu, Ph.D.
former Chairman, BayHelix and
Chairman & CEO, Apollomics Inc.
LinkedIn
Franck Le Deu
Senior Partner & Co-Leader of Asia Life Sciences Practice
McKinsey & Company
LinkedIn
Bin Li, Ph.D.
Founder, CEO & Chief Investment Officer
Lake Bleu Capital
LinkedIn
Wendy Pan, Ph.D.
Partner & Leader of Asia Life Sciences, Goodwin and
Chairwoman, BayHelix
LinkedIn
Debra Yu, M.D.
Partner and Chief Operating Officer
Panacea Venture
LinkedIn
Yong Ben, M.D.
Venture Partner
Eight Roads Ventures
Moreright-arrow

Present your Story to VCs and Pharma

Are you a biotech with cutting-edge innovation? Join the Presenting Company Class of 2025 to increase your visibility and drive partnering requests from VCs and BD teams. Limited space - submit your nominations today.

Apply to Present >>

Deliver Thought Leadership

Share your insights, elevate your brand and position yourself as a peer in BioCentury's network of biopharma decision-makers.

Learn More >>

See China’s innovation ecosystem up closeWhere data drives deals and development
REGISTER NOW